{"organizations": [], "uuid": "7301438352f6519d6d543f287f6ef365989260f3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-axovant-announces-negative-results/brief-axovant-announces-negative-results-for-intepirdine-in-phase-2b-headway-pilot-phase-2-gait-balance-studies-idUSFWN1P30IV", "country": "US", "domain_rank": 408, "title": "BRIEF-Axovant Announces Negative Results For Intepirdine In Phase 2B Headway, Pilot Phase 2 Gait, Balance Studies", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.383, "site_type": "news", "published": "2018-01-08T20:10:00.000+02:00", "replies_count": 0, "uuid": "7301438352f6519d6d543f287f6ef365989260f3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-axovant-announces-negative-results/brief-axovant-announces-negative-results-for-intepirdine-in-phase-2b-headway-pilot-phase-2-gait-balance-studies-idUSFWN1P30IV", "ord_in_thread": 0, "title": "BRIEF-Axovant Announces Negative Results For Intepirdine In Phase 2B Headway, Pilot Phase 2 Gait, Balance Studies", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "axovant sciences ltd", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "nelotanserin", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Axovant Sciences Ltd:\n* AXOVANT ANNOUNCES NEGATIVE RESULTS FOR INTEPIRDINE IN PHASE 2B HEADWAY AND PILOT PHASE 2 GAIT AND BALANCE STUDIES; POSITIVE TRENDS IN EFFICACY SEEN IN PILOT PHASE 2 NELOTANSERIN STUDY\n* AXOVANT SCIENCES LTD - INTEPIRDINE PROGRAM TO BE DISCONTINUED BASED ON MINDSET, HEADWAY, AND GAIT AND BALANCE STUDY RESULTS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T20:10:00.000+02:00", "crawled": "2018-01-09T17:03:57.038+02:00", "highlightTitle": ""}